Tango Therapeutics, Inc.
TNGX
$24.00
+5.73%
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing precision oncology therapies, with a pipeline centered on MTA-cooperative PRMT5 inhibitors for cancers such as pancreatic, lung, and glioblastoma. The company differentiates itself through its synthetic lethality platform, targeting genetic vulnerabilities in tumors to create novel drug candidates. Currently, the investor narrative is driven by the rapid advancement of its lead programs, TNG462 and TNG456, and the stock's remarkable re-rating over the past year, reflecting heightened expectations for clinical data and potential partnerships. The company's recent capital raises and positive analyst sentiment underscore the market's optimism about its pipeline's commercial potential.…
TNGX
Tango Therapeutics, Inc.
$24.00
Investment Opinion: Should I buy TNGX Today?
Rating: Buy. TNGX is a compelling speculative buy for investors with high risk tolerance, given the Strong Buy consensus and 87.4% upside to the average target of $44.75. The thesis is driven by the potential of its PRMT5 inhibitors to address significant unmet needs in oncology, with the stock's 240% one-year rally reflecting growing confidence.
Sign up to view all
TNGX 12-Month Price Forecast
The AI assessment is bullish with medium confidence, driven by the strong analyst sentiment and the stock's impressive momentum. However, the extreme valuation and lack of recurring revenue introduce significant risk. The stance would be upgraded to high confidence if clinical data shows clear efficacy, or downgraded to neutral if trials encounter setbacks. Key factors to monitor are the next earnings report and any clinical data releases.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Tango Therapeutics, Inc.'s 12-month outlook, with a consensus price target around $45.18 and implied upside of +88.3% versus the current price.
Average Target
$45.18
0 analysts
Implied Upside
+88.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$24 - $69
Analyst target range
TNGX is covered by 12 analysts, with a consensus recommendation of 'Strong Buy' and a mean rating of 1.23 (where 1 is Strong Buy and 5 is Sell). The average price target is $44.75, implying a substantial 87.4% upside from the current price of $23.88. The target range spans from a low of $24.00 to a high of $69.00, with the high target suggesting the potential for the stock to more than double, reflecting optimism about clinical data and market opportunity.
Bulls vs Bears: TNGX Investment Factors
TNGX presents a classic high-risk, high-reward biotech opportunity. The bull case is anchored by a Strong Buy consensus, a 240% one-year rally, and an innovative platform targeting large unmet needs. However, the bear case highlights extreme valuation multiples, escalating losses, and high short interest. Currently, the bull side has stronger evidence given the analyst conviction and clinical momentum, but the single most important tension is whether upcoming clinical data for TNG462/TNG456 will validate the market's high expectations. If data disappoints, the stock could fall sharply toward the 52-week low of $6.25; if positive, it could reach the $69 high target.
Bullish
- Strong Buy consensus with 87% upside: 12 analysts rate TNGX a Strong Buy (mean 1.23), with an average price target of $44.75, implying 87.4% upside from the current $23.88. The high target of $69 suggests potential for nearly 190% gains, reflecting strong confidence in the pipeline.
- Massive 240% one-year stock surge: TNGX has rallied 240.7% over the past year, from a 52-week low of $6.25 to a high of $34.39. This momentum, with a 95.7% gain over six months, indicates strong market conviction in the company's clinical progress and commercial potential.
- Innovative synthetic lethality platform: Tango's lead programs, TNG462 and TNG456, target MTAP-deleted cancers—a significant unmet need in pancreatic, lung, and glioblastoma. The platform's precision approach could yield first-in-class therapies, justifying premium valuation.
- Healthy balance sheet with low debt: Debt-to-equity is only 0.097, and the current ratio is 16.3, indicating ample liquidity to fund operations. This financial stability reduces bankruptcy risk and supports continued R&D investment.
Bearish
- Pre-revenue with escalating losses: Q1 2026 revenue was $0, and net loss widened to -$45.5 million from -$38.7 million in Q4 2025. R&D spending rose to $33.1 million, indicating cash burn that will require future dilution or partnerships.
- Extreme valuation multiples: P/S ratio is 16.5x and EV/Sales is 55.4x, both extremely high for a company with minimal revenue. This pricing implies the market expects massive future sales, leaving little room for disappointment.
- High short interest at 16.66: Short ratio of 16.66 days to cover suggests significant bearish sentiment. A negative catalyst could trigger a sharp selloff as short sellers press their advantage.
- Recent 15% one-month decline: TNGX fell 15.0% in the past month, underperforming the S&P 500's +2.45% gain. This pullback from the June high of $32.90 indicates profit-taking and potential momentum loss.
TNGX Technical Analysis
TNGX has exhibited a powerful uptrend over the past year, with the stock price surging 240.7% from a 52-week low of $6.25 to a high of $34.39. The current price of $23.88 sits at 69.4% of the 52-week range, indicating the stock is in the upper half of its yearly range, a sign of sustained bullish momentum. This positioning suggests that while the stock has pulled back from its highs, it remains in a strong long-term uptrend, with the 52-week low providing a significant support level.
Beta
1.12
1.12x market volatility
Max Drawdown
-32.2%
Largest decline past year
52-Week Range
$6-$34
Price range past year
Annual Return
+251.9%
Cumulative gain past year
| Period | TNGX Return | S&P 500 |
|---|---|---|
| 1m | -13.3% | -1.4% |
| 3m | -19.5% | +3.3% |
| 6m | +38.7% | +15.1% |
| 1y | +251.9% | +17.2% |
| ytd | +168.8% | +11.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TNGX Fundamental Analysis
Tango Therapeutics is a pre-revenue biotech, with Q1 2026 revenue of $0, consistent with the prior quarter's $0, but a stark contrast to the $53.8 million recognized in Q3 2025, which was likely from a one-time licensing deal. The company's net loss widened to -$45.5 million in Q1 2026 from -$38.7 million in Q4 2025, reflecting increased R&D spending of $33.1 million. The lack of recurring revenue and escalating losses highlight the company's dependence on its pipeline's success, with the path to profitability tied to clinical milestones and potential partnerships.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-142544000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TNGX Overvalued?
Given that TNGX has negative net income and EBITDA, the most appropriate valuation metric is the price-to-sales (P/S) ratio, which stands at 16.5x on a trailing basis. This is elevated for a company with minimal revenue, reflecting the market's high expectations for future sales. The EV/Sales ratio is even more extreme at 55.4x, indicating that the market is pricing in substantial future growth, likely from the successful commercialization of its PRMT5 inhibitors.
PE
-10.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-9.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: TNGX is pre-revenue with no recurring income, and Q1 2026 revenue was $0, while net losses widened to -$45.5 million. The company burned $142.5 million in free cash flow over the trailing twelve months, and with only $0.32 EPS loss in Q1, it will require substantial capital raises, likely diluting shareholders. The current ratio of 16.3 provides a cushion, but the escalating R&D spend of $33.1 million per quarter means cash runway is limited without additional financing or partnerships. The reliance on a single licensing deal for Q3 2025 revenue ($53.8 million) underscores the lack of stable revenue streams.